A concept and design for a revolutionary medical device aimed at critically ill patients
A granted-patent platform at the intersection of six large and growing industries
Hemocorr is a patented concept and design that would combine continuous real-time multi-analyte blood monitoring with selective, drug-free correction in a single extracorporeal loop — with reach extending across the sensor industry, AI, pharmaceuticals, animal research, and insurance.
Every component already exists. Centrifugal separation, membrane fractionation, multi-analyte sensing, and magnetic capture are each proven, in-market technologies. Hemocorr's patented invention is the platform that sequences them into a single continuous, closed loop — and it is modular by design: analyte count is a configuration choice, and correction is a separable stage that follows monitoring, so the same architecture supports a single-analyte monitoring-only device as readily as a full multi-analyte monitor-and-correct system.
A structural failure in critical care — confirmed by independent patent examination
Real-time ICU sensors today are single-analyte and structurally limited. Intravascular sensors are prone to clot formation and protein fouling. Interstitial sensors introduce a 4–15 minute lag and are subject to progressive biofouling. Transdermal optical sensors are blinded by tissue interference that compounds with every additional analyte targeted.
Correcting an abnormal level usually means a drug — with dosing uncertainty and side effects that scale with how sick the patient already is — or dialysis, which removes by size cut-off rather than by target, with no real-time feedback on whether it is working.
No existing commercial device combines real-time, multi-analyte sensing and multi-target, drug-free correction within a single extracorporeal loop. This is not simply the inventor's assessment: it is consistent with the finding of the European Patent Office, which assessed 41 of 44 claims as novel and inventive, stating that the invention "does not appear to be disclosed nor hinted at in the prior art" — and with the grant of patents by both the United States Patent Office and the Indian Patent Office.
Equally important is what Hemocorr would do to the existing industries that surround it. Today, real-time blood sensors are severely constrained by the environment in which they must operate — inside or on the body, contending with tissue, clotting, and interference. Hemocorr removes those constraints entirely, by moving measurement into a clean, controlled external plasma channel.
For sensor manufacturers, this means existing products would work better. For magnetic capture chemistry companies, it means their particles would function in a far cleaner medium. For AI companies, it means the continuous, high-resolution data their models need — and currently cannot get — would finally exist.
Hemocorr would not just occupy a gap in the device market. It would act as a platform multiplier for several adjacent industries simultaneously, each with its own large and growing market.
Six industries — one platform
Hemocorr would compete directly in two device categories and catalyse growth in four more. Each represents a distinct investment case and a distinct class of potential partner.
Critical care patient monitoring
The global critical care patient monitoring market is driven by ageing populations, rising chronic disease burden, and an accelerating push toward continuous, real-time monitoring. The ICU-specific segment alone is forecast to grow from $3.5B (2024) toward $5.7B by 2033.
Hemocorr would compete directly in this market as the only device offering continuous, real-time monitoring of dozens of blood analytes simultaneously — not just the three cardiovascular parameters that every ICU already watches.
Blood purification & extracorporeal therapy
The blood purification equipment market includes hemodialysis, CRRT, hemoperfusion, and plasma exchange. The sepsis and septic shock segment — most directly relevant to Hemocorr's correction capability — is growing at 14.2% CAGR, well above the category average.
Hemocorr would compete here as a far more selective and versatile alternative: multi-target correction without dialysate, without non-specific removal, with real-time monitoring integrated throughout.
Real-time medical sensors
The medical sensors market is growing rapidly — but existing real-time sensors are severely constrained by the environment in which they must work. Tissue interference, biofouling, protein fouling, single-analyte limitation, and the need for antifouling coatings all limit what sensor manufacturers can achieve in-vivo.
Hemocorr would remove every one of those constraints by moving measurement into a clean, controlled external plasma channel. Sensors that currently cannot function reliably in the body would function without limitation outside it. Sensor manufacturers would see their products perform better, reach more patients, and enter clinical applications that are currently not viable.
Magnetic capture chemistry
Magnetic bead technology — the basis of Hemocorr's drug-free correction mechanism — is already a multi-billion dollar market, currently used primarily in laboratory and diagnostic applications. In Hemocorr's extracorporeal circuit, magnetic particles would function as targeted therapeutic actuators.
At present, magnetic beads must work in whole blood — a complex medium with many competing molecules. Hemocorr's plasma fractionation provides a far cleaner environment. Fewer non-target molecules mean greater efficiency and specificity. The technical demands on designing effective capture particles are significantly reduced, lowering development costs and widening the range of viable therapeutic targets.
Artificial intelligence in critical care
The AI-based critical care market is forecast to grow at 30.30% per year — one of the fastest growth rates in any sector of medicine. Yet independent review of the evidence shows a persistent problem: a "translational gap between retrospective performance and clinically mature, safely deployable ICU AI." (ScienceDirect, 2025)
The gap exists because the data AI needs does not yet exist. Current AI models are trained on sparse, infrequent, single-analyte retrospective datasets. Hemocorr would generate, for the first time, continuous minute-by-minute blood chemistry time series across dozens of analytes in seriously ill patients — precisely the high-density, multi-variable input that predictive models require. Hemocorr would not just participate in the AI market: it would supply its fuel.
Pharmaceutical development & pharmacovigilance
For drugs aimed at critically ill patients — drugs with short onset of action, narrow therapeutic windows, and high adverse-effect risk — real-time continuous monitoring of drug action is currently impossible. Hemocorr would be the only platform capable of providing it.
In both human and animal-model drug development, Hemocorr would allow the dynamics of drug action, safety signals, and efficacy to be characterized with unprecedented precision and speed — transforming pharmacovigilance from retrospective signal detection into real-time monitoring.
Combined market influence across all six sectors
Across the six industries Hemocorr would directly address or catalyse, the combined market in 2025 is estimated at over $117 billion — with the AI-in-critical-care component alone forecast to reach $167 billion by 2033.
¹ Figures are third-party industry estimates from Mordor Intelligence, DataBridge Market Research, Grand View Research, 360iResearch, Allied Market Research, and similar sources. They describe broad industry categories, not forecasts of Hemocorr's addressable revenue. See disclaimer.
Downstream: the insurance industry
Better prognostic models — made possible by Hemocorr's continuous data stream — would allow insurers to stratify risk with a precision that is currently impossible. Patients who benefit from optimal monitoring could be identified earlier. Outcomes would become more predictable. The result: more accurate underwriting, reduced liability for patients receiving best-available care, and a potential reduction in premiums for those currently classified as high-risk. The financial exposure of the insurance industry to critical illness outcomes is substantial; even marginal improvements in prognostic accuracy have large economic implications.
All market figures are third-party industry estimates for broad sectors. They are not independent research commissioned on Hemocorr's behalf, have not been independently verified, and do not constitute a forecast of Hemocorr's future revenue or market share. See the full disclaimer at the foot of this page.
Patent protection already in place
Granted, not pending
United States Patent No. 12,350,039 and Indian Patent No. 567865 are both granted — not filed, not pending, not under examination.
Strong EPO examination outcome
The European Patent Office assessed 41 of 44 claims as novel and inventive; all 44 as industrially applicable. No prior art was found that disclosed or hinted at the invention.
Clean, unencumbered ownership
Dr. Bal Chander is the sole inventor and sole patent owner. There are no existing licensing agreements, no co-owners, and no funding obligations to third parties.
View & download the patent documents
All records are publicly available — no login required
US 12,350,039 B2
Blood analysis system · Inventor: Bal Chander · Granted July 8, 2025
IN 567865
Blood analysis system · Inventor: Bal Chander · Granted
At the Indian Patent Office portal, select Patent Search and enter patent number 567865. A CAPTCHA is required — there is no direct static link to an individual Indian patent record.
WO 2020/230153
PCT/IN2020/050415 · Published Nov 19, 2020 · Links to both national grants
Where Hemocorr stands today
- What exists: a granted patent describing a specific architecture built from individually proven components — extracorporeal circulation, plasma fractionation, multi-analyte sensing, and magnetised target-specific capture chemistry.
- What does not exist yet: an integrated, working prototype. No bench or animal validation of the assembled system has been published, and no clinical testing has occurred.
- Why engineering risk is lower than it appears: every individual subsystem already exists in validated clinical or laboratory use. The challenge is integration — not invention of new underlying science.
- Funding to date: none. The inventor is the sole owner of both patents and has self-funded the work to this point.
- De-risked by design: Hemocorr can be developed and deployed in stages. Analyte count is a configuration choice, not an architectural one — a single-analyte version is as valid a first product as a multi-analyte one. And because correction is a separable capability, addable per analyte within the same validated architecture, a monitoring-only device (one analyte or many) is a smaller, faster, lower-risk first product on the same design, with correction layered in as a later phase.
- What comes next: prototype engineering, bench and preclinical validation, and a regulatory pathway (FDA / CDSCO / EMA as applicable) before any clinical use.
- The case for investing now: first-mover IP is secured. The component technologies have matured. The clinical need is urgent. And the multi-industry opportunity means that returns are not confined to a single device category — they extend across sensors, AI, pharma, and beyond.
Partners across the full ecosystem
The inventor is seeking partners who can take a protected architecture and turn it into something that can be bench-tested, then clinically tested, then commercialised. The opportunity is open to partners from multiple industries.
Engineering & device partners
Organisations with capability in extracorporeal device design, microfluidics, in-line sensing, or magnetic separation systems — to design and build the integrated prototype.
Sensor manufacturers
Companies making real-time optical, electrochemical, or biosensors who would benefit from a platform that removes every constraint those sensors currently face — and dramatically expands the market for their products.
Magnetic capture & biotech firms
Companies working with magnetic nanoparticles, functionalised capture chemistry, or targeted molecular binding — whose products would perform better and reach new clinical applications via Hemocorr's plasma fractionation environment.
AI & data companies
Organisations building AI models for critical care prediction and clinical decision support — who need the continuous, multi-analyte, high-resolution blood chemistry data that only Hemocorr would be able to generate.
Pharmaceutical & drug development
Companies developing drugs for critically ill patients who need a real-time platform for monitoring drug action, safety signals, and efficacy in the most complex patient population — in both animal-model and early clinical settings.
Strategic & financial investors
Open to licensing, joint development, or equity partnership discussions — in whatever structure best fits a development-stage medical device with multi-sector implications. The inventor responds personally to every enquiry.
Dr. Bal Chander
Dr. Chander is an alumnus of the All India Institute of Medical Sciences (AIIMS), New Delhi, and currently serves as Professor in the Department of Pathology at Dr. Rajendra Prasad Government Medical College, Himachal Pradesh, India.
Hemocorr originated from his work in pathology and autopsy research — specifically, observations of unexpectedly wide variation in organ-level hormone concentrations that routine blood testing would never have revealed. That finding led him, over years of cross-disciplinary thinking, to the full architecture described in the patent: a platform that would watch the blood's molecular conversation in real time, and correct what was wrong without drugs.
The work is entirely self-funded. Dr. Chander holds both patents as sole inventor and sole assignee, with no existing licensing agreements and no co-ownership of any kind.
Let's talk
Dr. Bal Chander · Professor, Dept. of Pathology · Dr. RPG Medical College, H.P., India